Reference health
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
28/28 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 28 checked references that resolve
resolves10.1038/ng.2396
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
resolves10.1016/j.critrevonc.2015.03.001
Targeted therapies for small cell lung cancer: Where do we stand?
resolves10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
resolves10.1016/S0140-6736(15)01281-7
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
resolves10.1038/nature14011
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
resolves10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
resolves10.1126/science.aaf1490
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
resolves10.1016/S1470-2045(16)30098-5
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
resolves10.1200/JCO.2017.72.5069
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
resolves10.1097/JTO.0000000000000414
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
resolves10.1038/labinvest.2014.157
Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic
resolves10.1038/labinvest.2013.130
Programmed death ligand-1 expression in non-small cell lung cancer
resolves10.1038/s41467-018-05032-8
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
resolves10.1158/1078-0432.CCR-16-0150
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
resolves10.1158/1078-0432.CCR-16-3107
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
resolves10.1093/jnci/dju435
Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
resolves10.1158/2326-6066.CIR-14-0133
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
resolves10.1111/jcmm.13143
Selective blockade of B7‐H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma
resolves10.1158/1078-0432.CCR-15-2428
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
resolves10.1186/1476-4598-10-33
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
resolves10.1586/1744666X.2014.865519
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
resolves10.1016/j.ejca.2018.06.023
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
The 3 references without a DOI — listed, not checked
no DOI — not checkedKoinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5:39–50.
no DOI — not checkedVelcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig. 2013;00:1–10.
no DOI — not checkedMcLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung Cancer. JAMA Oncol. 2015;2:1–9.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1186/s40425-019-0540-1"><img src="https://citestamp.com/citestamped/10.1186/s40425-019-0540-1/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1186/s40425-019-0540-1)